FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111559095> ?p ?o ?g. }

• W2111559095 endingPage "511" @default.
• W2111559095 startingPage "505" @default.
• W2111559095 abstract "Recent studies have suggested the eradication rate for Helicobacter pylori infection with standard amoxycillin-clarithromycin-containing triple therapy as first-line treatment have fallen below 80%. Levofloxacin-containing triple therapy was proposed as an alternative. The aim of this study is to compare the efficacy and tolerability of the standard 7-day clarithromycin-containing triple therapy against the 7-day levofloxacin-containing triple therapy, and to assess whether the classical triple therapy is still valid as empirical first-line treatment for H. pylori infection in Hong Kong.Three hundred consecutive H. pylori-positive patients were randomized to receive either 1 week of EAL (esomeprazole 20 mg b.d., amoxycillin 1 g b.d., and levofloxacin 500 mg daily) or EAC (esomeprazole 20 mg b.d., amoxycillin 1 g b.d., and clarithromycin 500 mg b.d.). H. pylori status was rechecked by (13)C-urea breath test 6 weeks after treatment. Patients who failed either of the first-line eradication therapy were invited to undergo H. pylori susceptibility testing.H. pylori eradication was achieved in 128 of 150 (85.3%) patients in EAL and 139 of 150 (92.7%) patients in EAC groups, respectively (p = .043), for both intention-to-treat and per-protocol analysis. More patients in the clarithromycin- than the levofloxacin-containing therapy group developed side effects from the medication (21.3% vs 13.3%, p = .060). Nine patients (six from the EAL group and three from the EAC group) who failed their corresponding eradication therapy returned for susceptibility testing. All nine isolates were highly resistant to levofloxacin (minimum inhibitory concentration or MIC > 32 microg/mL), whereas only two of the six isolates from the EAL group were resistant to clarithromycin (MIC > 0.5 microg/mL).The standard 7-day clarithromycin-containing triple therapy is still valid as the most effective empirical first-line eradication therapy for H. pylori infection in Hong Kong, as prevalence of primary resistance of H. pylori to amoxycillin and clarithromycin remains low. Patients who failed their empirical first-line eradication therapy should undergo H. pylori susceptibility testing to guide further treatment." @default.
• W2111559095 created "2016-06-24" @default.
• W2111559095 creator A5000329741 @default.
• W2111559095 creator A5000753071 @default.
• W2111559095 creator A5008273813 @default.
• W2111559095 creator A5024705123 @default.
• W2111559095 creator A5028088604 @default.
• W2111559095 creator A5030534481 @default.
• W2111559095 creator A5031848511 @default.
• W2111559095 creator A5042275012 @default.
• W2111559095 creator A5048961644 @default.
• W2111559095 creator A5059509440 @default.
• W2111559095 creator A5064785792 @default.
• W2111559095 creator A5084155064 @default.
• W2111559095 creator A5089516018 @default.
• W2111559095 creator A5090532858 @default.
• W2111559095 date "2009-12-01" @default.
• W2111559095 modified "2023-10-12" @default.
• W2111559095 title "Clarithromycin-Amoxycillin-Containing Triple Therapy: A Valid Empirical First-Line Treatment for<i>Helicobacter pylori</i>Eradication in Hong Kong?" @default.
• W2111559095 cites W1485194876 @default.
• W2111559095 cites W1552362143 @default.
• W2111559095 cites W1965080494 @default.
• W2111559095 cites W1967943206 @default.
• W2111559095 cites W1989413302 @default.
• W2111559095 cites W1996509006 @default.
• W2111559095 cites W2003405710 @default.
• W2111559095 cites W2017681548 @default.
• W2111559095 cites W2034781642 @default.
• W2111559095 cites W2037555030 @default.
• W2111559095 cites W2038563426 @default.
• W2111559095 cites W2055557876 @default.
• W2111559095 cites W2059285031 @default.
• W2111559095 cites W2083645866 @default.
• W2111559095 cites W2084237287 @default.
• W2111559095 cites W2095226690 @default.
• W2111559095 cites W2098115835 @default.
• W2111559095 cites W2101730203 @default.
• W2111559095 cites W2105073170 @default.
• W2111559095 cites W2106040913 @default.
• W2111559095 cites W2108309284 @default.
• W2111559095 cites W2114196679 @default.
• W2111559095 cites W2114626239 @default.
• W2111559095 cites W2123569089 @default.
• W2111559095 cites W2143107875 @default.
• W2111559095 cites W2152211277 @default.
• W2111559095 cites W2171482459 @default.
• W2111559095 cites W4237662361 @default.
• W2111559095 cites W4376103839 @default.
• W2111559095 doi "https://doi.org/10.1111/j.1523-5378.2009.00722.x" @default.
• W2111559095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19889067" @default.
• W2111559095 hasPublicationYear "2009" @default.
• W2111559095 type Work @default.
• W2111559095 sameAs 2111559095 @default.
• W2111559095 citedByCount "39" @default.
• W2111559095 countsByYear W21115590952012 @default.
• W2111559095 countsByYear W21115590952013 @default.
• W2111559095 countsByYear W21115590952014 @default.
• W2111559095 countsByYear W21115590952015 @default.
• W2111559095 countsByYear W21115590952016 @default.
• W2111559095 countsByYear W21115590952017 @default.
• W2111559095 countsByYear W21115590952018 @default.
• W2111559095 countsByYear W21115590952019 @default.
• W2111559095 countsByYear W21115590952020 @default.
• W2111559095 countsByYear W21115590952021 @default.
• W2111559095 countsByYear W21115590952022 @default.
• W2111559095 crossrefType "journal-article" @default.
• W2111559095 hasAuthorship W2111559095A5000329741 @default.
• W2111559095 hasAuthorship W2111559095A5000753071 @default.
• W2111559095 hasAuthorship W2111559095A5008273813 @default.
• W2111559095 hasAuthorship W2111559095A5024705123 @default.
• W2111559095 hasAuthorship W2111559095A5028088604 @default.
• W2111559095 hasAuthorship W2111559095A5030534481 @default.
• W2111559095 hasAuthorship W2111559095A5031848511 @default.
• W2111559095 hasAuthorship W2111559095A5042275012 @default.
• W2111559095 hasAuthorship W2111559095A5048961644 @default.
• W2111559095 hasAuthorship W2111559095A5059509440 @default.
• W2111559095 hasAuthorship W2111559095A5064785792 @default.
• W2111559095 hasAuthorship W2111559095A5084155064 @default.
• W2111559095 hasAuthorship W2111559095A5089516018 @default.
• W2111559095 hasAuthorship W2111559095A5090532858 @default.
• W2111559095 hasConcept C126322002 @default.
• W2111559095 hasConcept C197934379 @default.
• W2111559095 hasConcept C2775981797 @default.
• W2111559095 hasConcept C2776409635 @default.
• W2111559095 hasConcept C2776962512 @default.
• W2111559095 hasConcept C2777172195 @default.
• W2111559095 hasConcept C2778204628 @default.
• W2111559095 hasConcept C2778375690 @default.
• W2111559095 hasConcept C2779708577 @default.
• W2111559095 hasConcept C2781276175 @default.
• W2111559095 hasConcept C2908868296 @default.
• W2111559095 hasConcept C501593827 @default.
• W2111559095 hasConcept C71924100 @default.
• W2111559095 hasConcept C86803240 @default.
• W2111559095 hasConcept C89423630 @default.
• W2111559095 hasConcept C90924648 @default.
• W2111559095 hasConceptScore W2111559095C126322002 @default.
• W2111559095 hasConceptScore W2111559095C197934379 @default.

• next